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A R T I C L E I N F O




Advanced glycation end product
Aging
Cytokines
A B S T R A C T
Chronic inflammation and Advanced Glycation End products (AGE) are associated with sarcopenia. Decreased
voluntary muscle activation and increased antagonist coactivation can contribute to age-related muscle weak-
ness. The influence of chronic inflammation and AGE in these neuromuscular mechanisms is not clear. We
studied whether a relation exists between circulating levels of inflammatory cytokines and AGEs as well as the
interplay between agonist and antagonist muscle activation. We studied 64 community-dwelling old subjects,
during a maximal isometric voluntary contraction (MVC) and a reaction-time (RT) test of the upper limb.
Twenty-five circulating inflammatory biomarkers were determined. Linear regression showed significant re-
lationships between chronic inflammation and six muscle activation parameters. MIP-1β showed a significant
negative relation with antagonist coactivation (during MVC) and antagonist muscle activity during pre-move-
ment time (PMT) and movement time (MT) (during RT). A higher level of pentosidine (AGE) was predictive for a
longer PMT. We conclude that in older relatively healthy persons antagonist muscle activation is influenced by
chronic inflammation, contributing to age-related muscle weakness. Our results also suggest a mechanical and
inflammatory influence of pentosidine in upper limb slowing of movement. These findings show novel insight in
underlying mechanisms of age-related muscle weakness.
1. Introduction
A chronic low-grade inflammatory profile (CLIP) is seen in most
aging people (Krabbe et al., 2004; Roubenoff, 2007). Changes in body
composition and decline of the immune system are underlying in
complex relationships (Jo et al., 2012; Wilson et al., 2017). It is well
known that CLIP is associated with muscle weakness (Beenakker et al.,
2010; Beyer et al., 2012) and frailty (Wilson et al., 2017). Since evi-
dence showed that age-related loss of muscle strength is only weakly
associated with the reduction in muscle mass (Clark and Manini, 2008;
Delmonico et al., 2009; Mitchell et al., 2012) it is accepted that neu-
romuscular mechanisms, contribute to age-related muscle weakness
(Clark and Manini, 2008; Clark and Manini, 2012). However the ex-
planatory mechanisms are not yet fully understood. Neuromuscular
mechanisms supposed to be involved are a deficit in voluntary muscle
activation and increased antagonist muscle coactivation. The involve-
ment of chronic inflammation in these mechanisms is not clear.
Another factor contributing to the aging process is the low turnover
of collagen, resulting in susceptibility to interact with metabolites, al-
lowing the accumulation of non-enzymatic glycation crosslinks, which
are irreversible and cause tissue stiffness (Avery and Bailey, 2006;
Semba et al., 2010b). Higher levels of these crosslinks, i.e. Advanced
Glycation End products (AGE) are independently related to decreased
walking abilities, inferior Activities of Daily Living (ADL), decreased
muscle properties (strength, power, mass) and increased physical frailty
(Drenth et al., 2016). Besides forming of crosslinks, AGE increase oxi-
dative stress and inflammation, through binding with one of the cell
surface Receptors for Advanced Glycation End products (RAGE) (Basta,
2008; Uribarri et al., 2007). This activation of RAGE leads to an ex-
acerbation of decreasing muscle strength and physical performance
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(Dalal et al., 2009; Semba et al., 2010a; Semba et al., 2010b). The in-
volvement of AGE in voluntary muscle activation is unclear.
We recently found an association between circulating cytokines and
contractile muscle properties (twitch force) during a fatigue protocol, in
healthy community dwelling elderly (Arnold et al., 2017). In another
study we provided evidence for the presence of an early antagonist
muscle coactivation in community-dwelling elderly during a reaction
time (RT) test, using fast dynamic movements (Arnold et al., 2015).
From a mechanical point of view, this early antagonist coactivation
may counteract the agonist muscle, resulting in delay in start of the
movement, longer RT and reduced net force production. Our previous
findings led to the purpose of this study, which is to answer the question
if a relation exists between circulating levels of inflammatory cytokine
and AGE and the interplay between muscle activation of agonist and




This study extends our previous investigations where participants
and measurement procedures have been described in detail (Arnold
et al., 2015; Bautmans et al., 2011). Here data from sixty-four com-
munity-dwelling elderly (32 males and 32 females, aged respectively
79.6 ± 4.1 and 79.6 ± 4.9 years) were analysed (see Table 1). They
were recruited via the University community, seniors associations,
poster and flyer advertisements, and mailings. Subjects were excluded
when presenting functional disability of the dominant upper extremity
(paresis/paralysis, tremor or recent surgery), cognitive decline (Mini
Mental State Examination (MMSE) score < 24/30 (Folstein et al.,
1975), neurologic disorders, acute or uncontrolled conditions, or
chronic inflammatory pathology. Stable morbidity was not an exclusion
criterion per se (Ferrucci et al., 2004). None of the participants was
involved in a specific training program or was a trained master athlete.
The study was approved by the Medical Ethics Committees of the
Universitair Ziekenhuis Brussel (Belgium) and the Erasmus Universitair
Medisch Centrum Rotterdam (The Netherlands); and all participants
gave written informed consent.
2.2. Measurements
2.2.1. Clinical characteristics
Height and weight were measured, and self-reported morbidity and
medication use were recorded. All participants completed the Yale
Physical Activity Survey (YPAS) questionnaire and the Activity
Dimensions Summary score (YPAS-ADS) was calculated, reflecting the
subject's physical activity (vigorous activity, leisure walking, moving,
standing and sitting) over the last month on a scale from 0 (no activity
at all) to 177 (maximal activity) (Dipietro et al., 1993). For descriptive
purposes dependency for basic activities of daily life (bADL) was rated
using a 6-item scale as described by Katz et al. (1963), complemented
by orientation in time and place. Each item was scored from 1 (com-
pletely independent or no problem ins orientation) to 4 (completely
dependent or completely disoriented). Dependency for instrumental
ADL (iADL) was evaluated using a 9-item questionnaire following
Lawton et al. (1982)). Each item was scored from 1 (completely de-
pendent) to 3 (completely independent). Cognitive functioning was
assessed using the Mini Mental State Examination (MMSE) (Folstein
et al., 1975). MMSE-scores> 23/30 were considered as normal.
2.2.2. Circulating markers of inflammation and AGEs
Serum levels of 25 different cyto-/chemokines were measured si-
multaneously by multiplex bead immunoassay (Human Cytokine
Twenty-Five-Plex, Biosource International, Nijvel, Belgium) according
to the manufacturer's indications, including: IL-1β, IL-1RA, IL-2, IL-2R,
IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-15, IL-17, CCL2/(MCP-
1), CCL3/(MIP-1α), CCL4/(MIP-1β), CCL5/(RANTES), CCL11/(Eo-
taxin), CXCL9/(MIG), CXCL10/(IP-10), TNFα, IFN-α, IFN-γ, and GM-
CSF. Two different AGEs were measured; Pentosidine en Carbox-
yMethylLysine (CML). Full names and sensitivities are reported in
Table 2. Data for samples below the detectable range were imputed as 1
decimal value below the detection limit. When>50% of the samples
were below the detection limit, the marker was excluded for statistical
analysis (see Table 2).
2.2.3. Measurement sequence
First, serum was collected by venepuncture from the non-dominant
arm and was frozen at −20 °c for later simultaneous determination of
circulating cytokines and AGEs. Next, participants' characteristics were
assessed and the subjects performed a maximal isometric voluntary
contraction (MVC) test of elbow flexion and extension, described by
Bautmans et al. (2011), in order to calculate the antagonist coactiva-
tion. After 5min. of recovery the participants performed a RT test
(Arnold et al., 2015; Bautmans et al., 2011) which was preceded by a
familiarization session (consisting in 15 trials). Both test setups are
described in detail in the supplementary material.
2.2.4. Surface electromyography and signal processing
Self-adhesive pre-gelled electrodes (Ag/Cl, 10mm diameter, 20mm
inter-electrode distance) were placed over the M. Biceps Brachii Caput
Breve, M. Triceps Brachii Caput Longum and one reference electrode on
the spinal processes of the seventh cervical vertebra (the skin was
cleaned using pure alcohol and shaved when necessary) according to
the SENIAM-recommendations (Hermens et al., 2000). sEMG sensors
were connected to a universal amplifier (MPAQ, IDEE/Maastricht In-
struments, Maastricht, The Netherlands) using shielded wires in order
to avoid movement artefacts. All raw sEMG signals were simultaneously
sampled at 12,500 Hz (Butterworth 4th order, band-pass 10–5000 Hz
and notch-filtered) and stored on a personal computer.
Signal processing was performed using data-acquisition software
(IdeeQ version 2.9b3, IDEE/Maastricht Instruments, Maastricht, The
Netherlands). For the RT-test, 28 stimuli were generated by the test
device. When errors occurred (i.e. when movement time > 3 s) the
system automatically generated a replacement stimulus. Additionally,
an observer recorded the wrongly executed trials during the RT-test
Table 1
Participants characteristics.
Characteristic Female (N=32) Male (N=32)
Age (years) 79.6 ± 4.9 79.6 ± 4.1
MMSE (score 0–30) 28.6 ± 1.6 28.6 ± 1.4
bADL-dependency (score 8–32) 8.3 ± 0.5 8.3 ± 0.6
iADL-dependency (score 9–27) 26.6 ± 0.7† 25.3 ± 2.3
YPAS-ADS (score 0–177) 51.9 ± 39.1 47.3 ± 25.3
MVC-triceps/agonist (N) 117.7 ± 39.2† 156.9 ± 49.0
Medication (number) 2.6 ± 3.0 2.6 ± 1.9
Co-morbidity* (number) 1.3 ± 1.4 1.9 ± 1.5
PMT (ms) 310.6 ± 39.6 311.5 ± 43.2
MT (ms) 302.8 ± 73.3† 252.5 ± 64.8
RT (ms) 618.6 ± 89.2† 571.8 ± 77.0
Mean ± SD; †=significant different from male (p < 0.05, independent t-
test); MMSE=Mini-Mental-State examination; bADL & iADL= respectively
basic and instrumental activities of daily life; YPAS-ADS=Activity Dimensions
Summary score of the Yale Physical Activity Survey; MVC=maximal voluntary
contraction; N=Newton, PMT=pre-movement time; MT=movement time;
RT= total RT; *Stabilized (chronic) conditions including hypertension, chronic
heart failure, diabetes type-2, chronic obstructive pulmonary disease, osteoar-
thritis, antecedents of cancer, antecedents of depression, elevated cholesterol.
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(e.g. when the subject missed the target pushbutton or made aberrant
movements with the arm). The correctly executed trials were confirmed
by offline visual inspection of the accelerometer signals. For each par-
ticipant, at least 23 correctly executed trials (stimuli) were available for
data analysis.
2.2.5. Muscle activation measures
In this study, the outcome variables were muscle activation mea-
sures that in previous studies showed a relation with slowness of
movement. Here we investigated 1) antagonist coactivation, calculated
from data obtained during the maximal isometric voluntary contraction
(MVC), 2) RT, 3) pre-movement time (PMT), 4) movement time (MT),
5) antagonist activity during PMT and 6) antagonist activity during MT,
7) antagonist muscle activation time relative to stimulus onset (PMAT)
and 8) antagonist muscle activation relative to movement onset (MAT).
Muscle parameters 2 to 8 were calculated from data obtained during the
RT test. Measurement procedures and calculations are described in the
supplementary material. See Fig. 1 and the list of abbreviations for an
additional explanation of the measures.
2.3. Statistical analysis
Data were analysed using IBM Statistical Package for the Social
Sciences (SPSS version 24.0). Differences in clinical characteristics ac-
cording to gender were analysed using independent t-test.
Inflammatory cytokines and AGEs were log(10)-transformed prior to
analyses to approximate the normality assumption. Multiple stepwise
linear regression was used to determine significant predictor variables
that produced the best model for RT measures. Gender, cytokines and
AGEs were used as independent variables and eight different muscle
activity measures as dependent outcome variables. Potential interaction
effects with sex were examined entering all significant factors into the
regression model. Cook's distance (> 1) and standardized residuals
(> 4) were checked to determine if cases might be influencing the re-
gression models. Significance was set a priori at p < 0.05.
3. Results
No significant difference was found between female and male in
age, MMSE-score, basic dependency scores, physical activity level,
number of medications, number of co-morbidities and pre-movement
time (see Table 1). Female showed significant higher instrumental de-
pendency scores, but men showed no problematic scores. As expected
females showed a significant longer MT and RT than males.
As can be seen in Table 2, IL-1β, IL-2, IL-5, IL-6, IL-7, IL-13, IL-15,
IL-17, GM-CSF, TNF-α and IFNγ levels were below the detection limit
in> 50% of the subjects.
3.1. Antagonist coactivation
Coactivation of the antagonist (M. Biceps) during agonist (M.
Triceps) MVC was related to female gender, log MIP-1β and log IL-1RA
accounting for 31% of the variability. Female showed higher coacti-
vation. No interaction effect of cytokines and female gender was found.
3.2. Reaction time
Regression analysis showed log transformed pentosidine to correlate
(β=0.017, ΔR2=0.06) significantly with PMT (see Table 3). 24% of
the variability in PMT can be predicted by the cytokine pathway ex-
pressed by a positive correlation with log IP-10 and a negative corre-
lation with log IL-1R (see Table 3). MT was significantly correlated with
female gender and log MIG in which log MIG explains 8%. No relation
was found between cytokines or AGEs and RT. Female showed longer
MT. No interaction effect of cytokines, pentosidine and female gender
was found.
3.3. Antagonist muscle activity
Muscle activity of the antagonist during PMT and MT showed sig-
nificant negative associations with log MIP-1β (β=−4.648 and –4.763
respectively) whereas female showed higher muscle activity. No inter-
action effect of cytokines and female gender was found.
3.4. Antagonist muscle activation time
No relation was found between cytokines or AGEs and the activation
time of the antagonist during the pre-movement-time (PMAT).
Activation time of the antagonist related to movement onset (MAT)
showed a significant negative association with log IL-2R (β=−0.053,
R2=0.123).
4. Discussion
This exploratory study for the first time shows the relation between
the chronic low-grade inflammation profile (CLIP), reflected by
Table 2
Circulating markers of inflammation.
pg/ml=picogram per milliliter; ng/ml= nanogram per milliliter; *=N=54;
IQR= interquartile deviation calculated as P75-P25; IL= interleukin; IL-
1RA= IL-1 receptor antagonist; GM-CSF=granulocyte macrophage colony-
stimulating factor; TNF-α= tumor necrosis factor alpha; IFN= interferon; IL-
2R= IL-2 receptor; IP-10= interferon γ-inducible protein 10;
MCP=monocyte chemoattractant protein; MIG=monokine induced by in-
terferon gamma; MIP=macrophage inflammatory protein;
RANTES=Regulated up-on Activation Normal T-cell Expressed and Secreted;
CML= carboxymethyllysine; When> 50% of samples in the group was below
the detection limit (shaded) the cyto/chemokine was excluded for statistical
analysis.
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inflammatory cytokines, and different muscle activation parameters,
probably contributing to slowing of muscle performance. The most
noticeable finding was the significant negative relation between MIP-1β
and 1) coactivation of the antagonist muscle during an isometric MVC
and 2) muscle activity of the antagonist muscle during PMT and MT
during a fast dynamic contraction, i.e. the RT test. In addition, a higher
level of pentosidine seems to be predictive for a longer PMT.
Markers of chronic low grade inflammation were significantly re-
lated with the degree of antagonist coactivation during maximal vo-
luntary isometric contraction, especially MIP-1β and IL-1RA with
respectively a negative and a positive association. These associations
show the involvement of chronic inflammation in peripheral antagonist
muscle coactivation during an isometric MVC. Our previous research
has already shown the correlation between contractile properties
(twitch force) of the M. adductor pollicis (acting as agonist muscle) and
MIP-1β and IL-1RA during an isometric contraction in a population of
relatively healthy elderly (Arnold et al., 2017). MIP-1β proteins med-
iate their biological function by binding to cell receptors and induce
intracellular effects leading to chemotaxis, degranulation and phago-
cytosis. Thus they play a key role in the induction and modulation of
inflammatory responses (Maurer and von Stebut, 2004). MIP-1β also
plays a key-role in muscle regeneration following muscle injury, due to
intensive resistance exercise (Mathers et al., 2012; Yahiaoui et al.,
2008). IL-1RA is a cytokine receptor acting as cytokine binding protein,
which can down regulate the effects of circulating cytokines (anti-in-
flammatory). Cytokine receptors tend to have longer half-lives than
their target cytokines, and as their secretion appears to parallel that of
the cytokine, they are good markers of chronic cytokine activity
(Morley and Baumgartner, 2004). Coactivation has been found to be
higher in older adults compared to younger persons, during isometric
contractions (Izquierdo et al., 1999; Macaluso et al., 2002; Rozand
et al., 2017). However studies regarding the influence of aging on an-
tagonist coactivation during isometric contractions in the upper limb,
by comparing young and old subjects, show contrasting results (Klass
et al., 2007). The negative association between MIP-1β and antagonist
coactivation in our participants most probably indicates an impairment
mechanism, since the major function of antagonist muscle activation in
elderly is to add to joint stabilization, as a compensatory mechanism
(Hortobagyi and Devita, 2006; Klein et al., 2001). Here we found an
effect of gender on coactivation of the antagonist muscle, indicating a
higher level of coactivation in females than males. Gender differences
during isometric contractions have been described related to accuracy
of movement and antagonist coordination (Brown et al., 2010; Yoon
et al., 2009), however the tasks performed in those studies were dif-
ferent. The gender difference might be explained by the lower mean
muscle strength in females compared to men, suggesting that the higher
coactivation is used as a compensation strategy for maintaining joint
stabilization, during isometric contractions.
PMT and MT, together reflecting RT, also showed significant posi-
tive associations with the cytokines IP-10 and MIG, and IL-1RA showed
Fig. 1. Signal plot during reaction time test. Plot of sEMG of antagonist muscle (Mm. Biceps) (for illustrative purposes full-wave rectified and RMS-smoothed over
2 ms) and signals of the pushbuttons during a single RT-stimulus in a female participant aged 85 years. T1= illumination of target pushbutton (visual stimulus, start
of PMT i.e. processing time), T2=participant releases the central pushbutton (end of PMT and start of MT), T3=participant presses the target pushbutton (end of
MT). PMAT=pre-movement activation time, MAT=movement activation time.
Table 3
Relationships between cytokines, AGEs and muscle parameters.
























Antagonist activation during MT
(Constant) 0.190*** 0.123
Log IL-2R −0.053*
*p < 0.05, **p < 0.01, ***p < 0.001; p-values are two-sided; R2= for
model.
a No interaction with female gender.
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an inverse relation with PMT. In addition, pentosidine showed a posi-
tive association with PMT. Both findings suggest that either by the
chronic inflammatory- or by the AGE-pathway PMT may be influenced.
Although the contribution of pentosidine in predicting PMT was small,
this was in line with our initial hypothesis that accumulation of cross-
linking AGE would contribute to slowing of muscle function. Our
finding confirms the research by Haus et al. (2007) who showed that
glycation-related cross-linking of intramuscular connective tissue may
contribute to altered muscle force transmission and decreased muscle
function in healthy aging elderly, explained by changes in the en-
domysial collagen tissues (Haus et al., 2007). The stiffness of passive
collagen tissues seems to hinder processing time. From a mechanical
point of view increased muscle activity of the antagonist gives re-
sistance to the agonist to generate force and the time to start the
movement, resulting in decreased force output and delay of the start of
the movement. Apparently CML, which is a non-cross-linking AGE, can
be considered less influential on the biomechanics of muscle tissue. Our
findings in previous research showed that the antagonist muscle ac-
tivity during PMT was significantly higher compared to the muscle
activity in young people (Bautmans et al., 2011). Here also an inverse
association was found between the antagonist muscle activity during
PMT and MT and the pro-inflammatory marker MIP-1β. The association
means that more inflammatory response, reflected by MIP-1β, is related
to lower antagonist muscle activity. This negative association probably
indicates an impairment of antagonist coactivation during dynamic
movements in elderly and in fact indicates an impairment of the joint
stabilizing mechanism. The effect of gender on muscle activity during
PMT and MT might be related to lower muscle strength and rate of force
development (RFD) known in females compared to males (Wu et al.,
2016) during dynamic contraction.
Previous work showed that additional to the higher muscle activa-
tion of the antagonist, the recruitment time of the antagonist during the
RT test of the upper limb (expressed as movement activation time
(MAT)), is longer in elderly compared to young participants (Arnold
et al., 2015). Here we found no association between CLIP and antago-
nist PMAT (i.e. the time necessary for stimulus reception, integration
and decision-making in the central nervous system, preparation of the
motor program, and sending motor commands to the muscles) and a
negative association between IL-2R (a cytokine receptor) and MAT. This
association accounts only for 12% of the variability in antagonist MAT.
Several authors described age-related changes in activation and in-
hibition patterns at the cortical level in elderly influencing the delay of
muscle activation (Bernard and Seidler, 2012; Burke and Kamen, 1996;
Heetkamp et al., 2014; Papegaaij et al., 2014). Our findings suggest that
CLIP, as another mechanism, is involved in altered muscle recruitment
patterns in elderly.
The complex interrelation and mediating role of inflammation-re-
lated markers and its association with declining muscle quality and
physical functioning has been known for many years (Calvani et al.,
2017; Peake et al., 2010). Cytokines that affect muscle function can be
produced in the muscle intrinsically or by neutrophils, macrophages,
fibroblasts, vascular smooth muscle cells and vascular endothelium
(Zoico and Roubenoff, 2002). In addition, also senescent cells can
contribute to low-grade inflammation, by an increase in the secretion of
pro-inflammatory cytokines which has been defined as the senescence
associated secretory phenotype (SASP) (Davalos et al., 2010; Sikora
et al., 2014). In our study we determined the most prominent SASP-
related biomarkers, including IL-8, IL-6, IL-1, MCP-1, eotaxin and MIP-
1α (related to MIP-1β) (Davalos et al., 2010). Since our participants
were relatively healthy and well-functioning, we expected that high-
sensitivity C-reactive protein (hs-CRP) - a common marker of in-
flammation which is used frequently in clinical practice to identify
patients with chronic inflammation - would be very low in most sub-
jects. Therefore, we choose not to determine hs-CRP, but a large set of
cyto/chemokines including both pro- and anti-inflammatory
biomarkers. It is beyond the scope of this study to explain the individual
function of each factor. More information about muscle protein de-
gradation pathways related to cytokine elevations can be found in the
review of Saini et al. (2009). Our findings show that in healthy elderly
CLIP is involved in voluntary activation and coactivation of the an-
tagonist, and should motivate clinicians to consider it as targets for
therapeutic interventions. The more because exercise as a strong anti-
inflammatory strategy has been proven to be effective (Mathur and
Pedersen, 2008; Pedersen and Saltin, 2015).
Our findings show positive as well as negative relationships between
the inflammatory markers and muscle activity. The interplay between
pro-inflammatory cytokines (negative relations with MIP-1β, IP-10,
MIG, IL-2R) and anti-inflammatory ones (positive relations with IL-
1RA) in our regression model, suggest that a balance between pro- and
anti-inflammatory signaling is involved in muscle activity.
The relationship between the antagonist muscle activation para-
meters and cytokines and AGEs has not been investigated before.
Exploring the possible relationships between the complex interrelated
cytokines and AGEs, and the muscle outcomes of interest by using the
regression method revealed relations contributing to age-related
changes in muscle activation.
Pentosidine was included as an independent predictor together with
inflammatory cytokines. Since AGE's can have both a mechanical and
inflammatory action on muscle performance, the impact of pentosidine
on slowing of movement might have been underestimated. Probably
this was not the case as no significant correlations between the cyto-
kines and pentosidine were found, which legitimates to interpret pen-
tosidine as an independent variable in the model.
Since the presence of stable comorbidities was not an exclusion
criterion per se, it cannot be excluded that other factors related to
chronic disease or treatment might have influenced muscle perfor-
mance in our participants. However, the number of medication was
very low, with a mean of 2.6. All participants were free of functional
limitations in the dominant arm. It is well known that cholesterol-re-
ducing medication such as statins can have adverse effects including
myalgia (Iwere and Hewitt, 2015). However only six subject (< 10%)
used statins and none reported muscle pain. Therefore, it is very un-
likely that our results were affected by statin use. By allowing partici-
pation of subjects with stable chronic conditions we were able to recruit
a representative sample of well-functioning older adults and thus our
results are more likely to be generalizable than when we would have
selected older persons completely free of any comorbidity and medi-
cation use. In our study, neither number of medications nor co-
morbidities showed significant relationships with muscle activity out-
comes (data not shown). However, the impact on muscle performance
of chronic conditions and commonly used medication at older age
merits further investigation.
The scores of the YPAS-ADS also have been entered in the regression
models as a covariate. The result showed the subject's physical activity
level to be predictive for movement time. Lower activity level was as-
sociated with longer movement time. However, the association must be
interpreted as negligible (β=−0.001, p=0.016).
Research in this domain allows qualifying a sample size of 64 as “a
high number”. However, given the large number of variables in the
study, we cannot completely exclude that some associations – although
statistically significant -were identified by chance. This first exploration
should therefore be followed by research in a larger sample in order to
confirm the relationships. However, the number of independent pre-
dictors retained in the regression models were restricted to 3 or less,
thus the sample size of our study is likely to be sufficient (at least
n=20 per predictor) to obtain valid analyses. The relatively high mean
age (79.6 years) of our elderly participants suggests that age-related
changes in the neuromuscular system have taken place, thus the sample
size is representative, contributing to the relevance of our findings.
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5. Conclusions
We can conclude that regression analysis showed significant re-
lationships between circulating cytokines and AGE (pentosidine) and
muscle activation parameters during isometric MVC and fast dynamic
contractions of the upper arm muscles in community-dwelling elderly.
These findings are the first to provide evidence for the involvement of
the chronic low-grade inflammatory profile in antagonist muscle acti-
vation, contributing to age-related muscle weakness. The results also
suggest a mechanical and inflammatory influence of the cross-linking
AGE, pentosidine, in slowing of movement. More research is necessary
to determine causal relations. However our results show novel insight
in underlying mechanisms of age-related muscle weakness and likely
contribute to developing more targeted interventions, aimed at coun-
tering muscle weakness in elderly.
Abbreviations
RT Reaction Time: pre-movement time+movement time
(msec.)
PMT pre-movement time: time for stimulus processing (msec.)
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